According to FiercePharma's rankings of this very morning, despite the Wyeth sale to Pfizer exceeding Schering-Plough's sale to Merck by almost 50 percent in size [$68 billion (Pfizer) v. $41 billion (Merck)], the Ex-CEO of Wyeth didn't even crack the top ten.
I bet you can guess who was No. 1 on the list of the most overpaid Pharma CEOs in 2009. The No. 1 "eye-popper" beat the guy who wiped out his company, by over three-fold. He also beat the guy who survived, and closed the deal, at Pfizer -- by well-over three fold. Yep, that's "Fast" Freddie Hassan! [Note that the figures in the overall graphic at right need to be "grossed up" -- by about an additional 30 percent or so, so the top end -- $173.4 million, at $28 -- looks more like $225.4 million, at around $36/share for New Merck. And, remember to add about $9 million to the total -- for every $1 of increase on the NYSE in New Merck's per share stock price, over $36.] Do go read it all, but here's a snippet:
. . . .Welcome to to our annual look at the biggst CEO paychecks in the pharma industry. . . .
1. Fred Hassan | Schering-Plough | $49.65 Million. . .
6. Richard Clark | Merck | $16.8 Million. . .
8. Jeffrey Kindler | Pfizer | $14.8 Million. . . .
H/T to my anonymous commenters, for pointing me to the FiercePharma story.
UPDATED @ 1 PM EDT -- The New York Times' Prescriptions Blog is now running a similar story. The Times reminds that Ex-CEO Hassan has his "deal goggles" back on, at privately-held Bausch & Lomb -- where he's landed as board chairman.